Skip to content

Real world study on the treatment of acute ischemic stroke with three points bleeding therapy

Real world study on the treatment of acute ischemic stroke with three points bleeding therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001120
Enrollment
Unknown
Registered
2025-06-06
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

control group:conventional therapy
Treatment group:Three points bleeding therapy combined with conventional therapy

Sponsors

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnosis of AIS(refer to the diagnostic criteria for AIS formulated in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023": a. Acute onset b. Defects in the local kitchen nerve function with a few cases being generalized neurological deficits; c. The imaging shows the responsible lesion or symptoms/signs for more than 24 hours; d. Rule out non-vascular causes; e. Brain CT/MRI to rule out cerebral hemorrhage; 2. Within 7 days of acute onset; 3.18 years old or younger gender not limited; 4.NIHSS=4 points; 5. Voluntary participation: The patient or their immediate family members can and are willing to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Transient ischemic attack or cerebral embolism caused by brain tumor brain trauma cardiogenic embolism etc.; 2. Patients who had received other vascular opening treatments before enrollment such as intra-arterial thrombolysis endovascular thrombectomy angioplasty and stenting etc. 3. Patients who received thrombolytic therapy before enrollment including recombinant tissue plasminogen activator urokinase tenecteplase etc. or intravenous antiplatelet drugs such as tirofiban; (4) a history of severe coagulopathy systemic bleeding (including platelet count 1.7 or PT>15s); 5. Patients with serious primary diseases of cardiovascular hepatic renal and hematopoietic systems and psychiatric disorders (including addiction and drug use disorders dissociative disorders and schizophrenia); 6. Patients who are pregnant lactating or have recent plans to have children.

Design outcomes

Primary

MeasureTime frame
National Institutes of Health Stroke Scale score;

Secondary

MeasureTime frame
The proportion of patients with good outcomes;Glasgow Coma Scale;National Institutes of Health Stroke Scale score;Modified Barthel Index;All-cause mortality rate;Stroke recurrence rate;

Countries

China

Contacts

Public ContactWu Dahua

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)

893049352@qq.com13508491768

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026